Covington & Burling (Washington)

Michael Labson

Covington & Burling (Washington)
Lawyer (Partner)

Michael Labson provides strategic advice to pharmaceutical and biotechnology clients in dealing with the FDA and other agencies. He has litigated a variety of cases in the life sciences area, and works actively on corporate transactions and government investigations. Mr. Labson’s recent work has involved issues such as clinical trial conduct; FDA dispute resolution; orphan drug, pediatric and Hatch-Waxman market exclusivities; real world evidence; product promotion and scientific exchange; REMS; pharmacovigilance; Rx/OTC switches; and DEA regulation of controlled substances. Drawing on his 20+ years of experience working for the biopharmaceutical sector on a wide array of issues, he provides clients creative and practical solutions to solve their regulatory challenges.

Linked authors

Covington & Burling (Brussels)
Covington & Burling (Brussels)
Covington & Burling (Brussels)
Covington & Burling (Washington)
Covington & Burling (Palo Alto)

Articles

22 Bulletin

Michael Labson, Geoffrey Hobart, Eric Holder, Mark Lynch, Richard Kingham, Peter Safir, Theodore Voorhees Jr, James R. Dean, David W. Addis, Ethan M. Posner The US FTC announces its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals

22

On April 4, 2006, the FTC published notice of its intention to conduct an extensive study of the economic effects of authorized generic pharmaceuticals. See 71 Fed. Reg. 16,779 (April 4, 2006). The initial stage of the study would involve detailed information requests, akin to subpoenas, to as (...)

Send a message